Mutations in RUNX1 were the most common non-ABL1 mutations among patients with BP-CML, mostly among those with a myeloid blast phenotype, an association reported in previous studies [8]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.